• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo
- - - - -

Resveratrol and beta-cells


  • Please log in to reply
No replies to this topic

#1 inawe

  • Guest
  • 653 posts
  • 3

Posted 27 August 2008 - 10:55 PM


If we do accept that RSV does indeed up-regulate the action of Sirt1; does the following mean that pregnant women shouldn't take RSV?

Mol Cell Biol. 2008 Aug 18. [Epub ahead of print]
Histone deacetylase inhibitors modify pancreatic cell fate determination and amplify endocrine progenitors.
Haumaitre C, Lenoir O, Scharfmann R.
INSERM U845, Centre de Recherche Croissance et Signalisation, Université Paris Descartes, Faculté de Médecine, Hôpital Necker, 75015 Paris, France.
During pancreas development, transcription factors play critical roles in exocrine and endocrine differentiation. Transcriptional regulation in eukaryotes occurs within chromatin and is influenced by post-translational histone modifications (e.g. acetylation) involving histone deacetylases (HDACs). Here, we showed that HDAC expression and activity are developmentally regulated in the embryonic rat pancreas. We discovered that pancreatic treatment with different HDAC inhibitors (HDACi) modified the timing and determination of pancreatic cell fate. HDACi modified the exocrine lineage via abolition and enhancement of acinar and ductal differentiation, respectively. Importantly, HDACi treatment promoted the NGN3 pro-endocrine lineage leading to an increased pool of endocrine progenitors and modified endocrine sub-type lineage choices. Interestingly, treatments with Trichostatin A and sodium butyrate, two inhibitors of both class I and class II HDACs, enhanced the pool of beta-cells. These results highlight the role of HDACs at key points in exocrine and endocrine differentiation. They show the powerful use of HDACi to switch pancreatic cell determination and amplify specific cellular sub-types, with potential applications in cell replacement therapies in diabetes.
PMID: 18710955 [PubMed - as supplied by publisher]




0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users